Australia/New Zealand

Current Distributors Profiles

Our network of distributors includes niche market players dedicated to a particular life science field.  They represent a variety of manufacturers products that are part of the workflow within that particular field.  They also have similar products, but each has a specific feature that becomes a differentiator to the benefit of their customers.  They have a team of highly technical and experienced sales people.  Serving a particular field also allow building a strong relationship with a network of Key Opinion Leaders in that field, as well as Core Laboratories.  Marketing efforts include KOL engagement and education, targeted email campaigns, and attendance at key conferences.

b2b connect has a number of niche distributors in Australia that we can contact to see which one may be a good fit with your product portfolio.

Market

Australia signaled its interest in expanding its biopharma industry into genomics in 2019, when its national government agreed to spend A$500 million (about $335.3 million) over the next decade on the nation’s first human genome project. The Australian Genomics Health Futures Mission is intended to foster and fund new research, clinical trials, and technologies, all with the goal of helping Australians live longer and better by expanding access to genomics knowledge and technology.

Also in 2019, the government unveiled reforms to its research and development tax incentive (R&DTI) that spared companies from lifetime caps on their refunds, and exempted clinical trials from a A$4 million ($2.8 million) cap on the annual refundable amount—prompting a sense of relief from industry group AusBiotech.

The “island continent” makes its strongest showing in its number of companies, where it has climbed to fourth with 876, according to AusBiotech—281 drug developers, 270 food/agricultural concerns, and 325 “medical technology,” a category that includes diagnostics. “Down Under” landed at the center of this year’s list in patents (6556 listing at least one Australian inventor, according to WIPO) and in jobs (69,108, also according to AusBiotech)—and placed only one position lower in R&D (A$31.179 billion [$22.153 billion] in 2015–16, according to the Australian Bureau of Statistics) and in IPOs (five companies raising a combined A$51.4 million [$36.7 million)].